Clinical Trials Browser

Fanconi Anemia, Complementation Group D1, Carcinoma, Ovarian Epithelial, Breast Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Ewing, Small Cell Lung Carcinoma

NCT03070548 2018-12-17

A Study of Talazoparib in Patients With Advanced Solid Tumors

Phase 1 Completed

6 enrolled 34 charts

Other solid neoplasm

Advanced Solid Tumors

NCT02836028 2018-09-18

A Study Evaluating Talazoparib in Relapsed Ovarian, Fallopian Tube, and Peritoneal Cancer

Phase 2 Withdrawn

Gynecologic

Ovarian Neoplasms

NCT01399840 2017-09-15

Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies

Phase 1 Completed

33 enrolled

LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Lymphoma, Mantle-Cell

Clinical Trials

TALAPRO-2

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors

Korea Post Marketing Surveillance (PMS) Study of Talzenna®

TRESR

TNBC

Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

Pre-approval Single-patient Expanded Access for Talazoparib (PF-06944076)

A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors

A Phase 1 Study Of Talazoparib, PARP Inhibitor, In Japanese Patients With Advanced Solid Tumors

A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer

Treatment Patterns and Clinical Outcomes Among Talazoparib-Treated Adults With HER2-Negative mBC With gBRCA1/2m

Real-World Outcomes of US Talazoparib-Treated Patients With Locally Advanced or Metastatic Breast Cancer

Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors

Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors

JAVELIN OVARIAN PARP100

Open-Label Extension and Safety Study of Talazoparib

Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors

EMBRACA

Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer

Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors

A Study to Evaluate the Effect of Itraconazole and Rifampin on the Pharmacokinetics of Talazoparib in Patients With Advanced Solid Tumors

An Open-Label Pharmacokinetics and Safety Study of Talazoparib

A Study to Assess the Effects of Talazoparib on Cardiac Repolarization in Patients With Advanced Solid Tumors

ABRAZO

Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors

A Study of Talazoparib in Patients With Advanced Solid Tumors

A Study Evaluating Talazoparib in Relapsed Ovarian, Fallopian Tube, and Peritoneal Cancer

Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies